A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy

Phosphodiesterases as therapeutic targets for respiratory diseases

(2019) Haoxiao Zuo et al.   PHARMACOLOGY & THERAPEUTICS

A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease

(2019) Dave Singh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD

(2018) Dave Singh et al.   EUROPEAN RESPIRATORY JOURNAL

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

(2017) Jørgen Vestbo et al.   LANCET

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

(2013) D. A. Mahler et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

(2013) Lui G Franciosi et al.   Lancet Respiratory Medicine

Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease

(2009) Katharine H Banner et al.   BRITISH JOURNAL OF PHARMACOLOGY

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET